Comments
Suven Life Sciences today announced that the company has obtained two product patents from Europe corresponding to the New Chemical Entities for the treatment of disorders associated with neurodegenerative diseases. The patents are valid through 2023 & 2029.
The Hyderabad-based, Suven Life is trying to develop the compounds into therapeutic agents that are useful in the treatment of disorders like Alzheimer’s disease, Attention Deficient Hyperactivity Disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.
With these new patents, Suven has about 13 granted patents in Europe. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II, Venkat Jasti, CEO, said in a press release.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.